Drugs / GEN1107
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06171789 | Jan 2024 → Aug 2025 | endometrial cancer, gastroesophageal cancer, non-small cell lung carcinoma, ovarian cancer +2 | Genmab | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN1107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06171789 ↗ |
| Route | Intravenous | “via intravenous (IV) infusion” NCT06171789 ↗ |
| Target | PTK7 | “a protein tyrosine K 7 (PTK7) targeted antibody-drug conjugate (ADC)” NCT06171789 ↗ |